[1]袁雪超 路玉峰 鲁超 张高魁 郭浩 刘德玉 郝阳泉.龙元通络生骨颗粒治疗早期激素性股骨头坏死40例[J].中国中医骨伤科杂志,2021,29(03):70-74.
　YUAN Xuechao LU Yufeng LU Chao ZHANG Gaokui GUO Hao LIU Deyu HAO Yangquan.Evaluation of the Clinical Efficacy of Longyuan Tongluo Shenggu Keli in the Treatment of Early Glucocorticoid-Induced Osteonecrosis of the Femoral Head[J].Chinese Journal of Traditional Medical Traumatology & Orthopedics,2021,29(03):70-74.
点击复制

龙元通络生骨颗粒治疗早期激素性股骨头坏死40例()
分享到：

《中国中医骨伤科杂志》[ISSN:1005-0205/CN:42-1340/R]

卷:
第29卷
期数:
2021年03期
页码:
70-74
栏目:
临床报道
出版日期:
2021-03-15

文章信息/Info

Title:
Evaluation of the Clinical Efficacy of Longyuan Tongluo Shenggu Keli in the Treatment of Early Glucocorticoid-Induced Osteonecrosis of the Femoral Head
文章编号:
1005-0205(2021)03-0070-05
作者:
袁雪超 路玉峰 鲁超 张高魁 郭浩 刘德玉 郝阳泉
1陕西中医药大学(陕西 咸阳,712000)2西安交通大学附属红会医院3陕西中医药大学附属医院名医馆△通信作者 E-mail:haoyq2008@163.com
Author(s):
YUAN Xuechao LU Yufeng LU Chao ZHANG Gaokui GUO Hao LIU Deyu HAO Yangquan
1Shaanxi University of Traditional Chinese Medicine,Xianyang 712000,Shaanxi China; 2Honghui Hospital,Xi’an Jiaotong University,Xi’an 710054,China; 3Famous Medical Center of Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine,Xianyang 712000,Shaanxi China.
关键词:
激素性股骨头坏死;  早期;  龙元通络生骨颗粒;  疗效
Keywords:
glucocorticoid-induced osteonecrosis of the femoral head;  early stage;  Longyuan Tongluo Shenggu Keli
分类号:
R681.8
文献标志码:
B
摘要:
目的:观察龙元通络生骨颗粒治疗早期激素性股骨头坏死的有效性及安全性。方法:选取2018年1月至2018年12月使用龙元通络生骨颗粒治疗的ARCO Ⅱ期激素性股骨头缺血性坏死患者40例,平均年龄(44.2±9.5)岁,平均发病时间(0.6±0.2)a。临床评估采用VAS疼痛评分及Harris髋关节评分,影像学评估采用X线评分,使用单因素ANOVA对比患者治疗前、治疗后3个月和9个月的情况。结果:患者治疗后3个月和9个月的VAS疼痛评分较治疗前明显降低,差异有统计学意义(P<0.05)。治疗后3个月和9个月的Harris评分明显高于治疗前,差异有统计学意义(P<0.05)。治疗前、治疗后3个月和治疗后9个月之间的X线评分无明显差异,差异无统计学意义(P>0.05)。所有患者服药期间均未出现不良反应。结论:采用龙元通络生骨颗粒治疗早期激素性股骨头坏死临床疗效可靠,具有较高的安全性。
Abstract:
To investigate the efficacy and safety of Longyuan Tongluo Shenggu Keli in the treatment of early glucocorticoid-induced osteonecrosis of the femoral head.Methods:40 patients with ARCO stage Ⅱ glucocorticoid-induced osteonecrosis of the femoral head treated by Longyuan Tongluo Shenggu Keli were reviewed from January 2018 to December 2018.The average age was(44.2±9.5)years old,and the average time of onset was(0.6±0.2)years old.Clinical evaluation used VAS pain score and Harris hip score.Imaging evaluation used X-ray score,and one-way ANOVA test was used to compare patients’ outcome before treatment,3 months and 9 months after treatment.Results:The VAS pain scores of patients 3 and 9 months after treatment were significantly lower than those before treatment(P<0.05).The Harris scores at 3 and 9 months after treatment were significantly higher than those before treatment(P<0.05).There was no significant difference in X-ray scores among before treatment,3 months after treatment and 9 months after treatment(P>0.05).All patients had no adverse reactions during the medication.Conclusion:Longyuan Tongluo Shenggu Keli has reliable clinical efficacy and high safety to treat early glucocorticoid-induced osteonecrosis of the femoral head.

参考文献/References:

[1] LIU F,WANG W,YANG L,et al.An epidemiological study of etiology and clinical characteristics in patients with nontraumatic osteonecrosis of the femoral head[J].J Res Med Sci,2017,22(1):15.
[2] 何伟.精确诊断前提下股骨头坏死非手术治疗实践[J].临床外科杂志,2017,25(8):580-582.
[3] UESUGIY,SAKAI T,SEKI T,et al.Quality of life of patients with osteonecrosis of the femoral head:a multicentre study[J].Int Orthop,2018,42(7):1517-1525.
[4] 鲁超,周永春,郝阳泉,等.通络生骨方治疗激素性股骨头坏死的回顾性临床研究[J].西部中医药,2016,29(9):105-108.
[5] 陈卫衡,何伟,童培建,等.股骨头坏死中医辨证标准(2019年版)[J].中医正骨,2019,31(6):1-2.
[6] 李子荣.骨坏死[M].北京:人民卫生出版社,2012:126 127.
[7] KUMAR P,SEN R,RAJNISH R K,et al.Reliability of modified harris hip score as a tool for outcome evaluation of total hip replacements in Indian population[J].J Clin Orthop Trauma,2019,10(1):128-130.
[8] 陈卫衡.基于X线的股骨头坏死保髋疗效评价方法研究[J].中华关节外科杂志(电子版),2017,11(3):4-9.
[9] 陈卫衡,林娜,王胜,等.非创伤性股骨头坏死与激素、酒精的相关性硏究[J].中国医药导报,2006,32(2):16-18.
[10] CHEN X,ZHANGL,MA H,et al.Lipid transporter activity-related genetic polymorphisms are associated with steroid-induced osteonecrosis of the femoral head:an updated meta-analysis based on the GRADE guidelines[J].Front Physiol,2018,9:1684.
[11] 李子荣.股骨头坏死:早期诊断与个体化治疗[J].中国矫形外科杂志,2013,21(19):190-191.
[12] 王丹彤,聂云天.口服中药治疗早中期股骨头缺血性坏死的疗效分析[J].内蒙古中医药,2017,36(5):7.
[13] 冯居平.活骨汤联合介入和西药治疗早期股骨头坏死50例[J].中医研究,2017,30(1):29-31.
[14] 李欢欢,李军,王秋霞.通络生骨方治疗股骨头骨髓水肿综合征的前瞻性临床研究[J].中国中医骨伤科杂志,2019,27(7):27-31.
[15] 李永志,董博,袁普卫.骨复生对激素性股骨头坏死大鼠骨组织中OPG及RANK表达的影响[J].中国中医骨伤科杂志,2018,26(11):1-6.
[16] 韩廷成,祁兆建,田敏,等.强筋壮骨丸联合髓芯减压腓骨棒支撑治疗早中期股骨头坏死30例临床观察[J].湖南中医杂志,2020,36(2):62-64.
[17] 张鑫杰,曹玉举,郭永昌,等.骨坏死康复丸治疗60例脾肾阳虚型股骨头缺血性坏死[J].世界中医药,2020,15(3):143-146.
[18] 潘细贵,修忠标,江陟郝,等.补肾活血法治疗ONFH机制的研究进展[J].江西中医药,2014,40(12):76-78.
[19] 林忆龙,文亦磊,奉建芳,等.龙血竭化学成分及药理作用研究进展[J].中国民族民间医药,2020,29(3):54-59.
[20] 袁普卫,欧国峰.补肾活血方对激素性股骨头坏死大鼠股骨头组织中RANKL、Cbfα1表达的影响[J].中医杂志,2019,60(9):779-783.
[21] 王一战,苏芮,范吉平,等.中药配方颗粒的发展现状及思考[J].上海中医药杂志,2016,50(11):16-19.

备注/Memo

备注/Memo:
基金项目:西安市卫生科研人才项目(J201903058)陕西省科技厅-社发攻关项目(2020SF-287)中西医结合治疗激素性股骨头坏死的临床研究(2020-ZXY-010)
更新日期/Last Update: 2021-03-15